secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023201
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx Q3 2022 revenue of $187.3M beats guidance; adjusted EBITDA margin 27.8%
------------------------------------------------------------------------------

- Total revenue $187.3M exceeded previously announced guidance; net loss $41.7M (22.3% margin) with $29M stock-based comp.
- Adjusted Net Income $29.9M (16.0% margin); Adjusted EBITDA $52.0M (27.8% margin) also beat guidance.
- Subscription and pharma manufacturer solutions grew double-digits; over 865k prescribers active in last 16 months.
- Net cash from operations $33.7M; exit quarter with over 7M consumers of prescription-related offerings.
- Management cited grocer issue impact but noted resilient retail/PBM partnerships and focus on profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000095017022023201/0000950170-22-023201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000095017022023201/gdrx-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer